10 mg · 20 mg · 30 mg · 50 mg
Retatrutide
Investigational peptide targeting GIP, GLP-1 and glucagon receptors. Studied in clinical trials on body weight and glycemic control.
For research use only
PT-141
Bremelanotide, a melanocortin agonist. Studied in sexual response, including trials in premenopausal women with hypoactive sexual desire disorder.
- Pay by card (Stripe) or Zelle
- Ships within the U.S. with tracking
- Questions? Call or email us
Benefits under study
Bremelanotide trials in premenopausal women with hypoactive sexual desire disorder.
- Improved sexual desire
- Reduced associated distress
- Melanocortin signaling
Research overview
PT-141 (bremelanotide) is a synthetic peptide analog of α-melanocyte-stimulating hormone that acts on melanocortin receptors, particularly MC4R.
Two randomized phase 3 trials published in Obstetrics & Gynecology evaluated bremelanotide in premenopausal women with hypoactive sexual desire disorder, measuring desire and related distress.
Supplied as a 10 mg vial for laboratory research.
Scientific references
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Obstet Gynecol, 2019 · PMID 31599840
View on PubMed
You may also need
10 mg · 20 mg
Tesamorelin
GHRH analog studied in GH/IGF-1 signaling and visceral fat, including trials in people with HIV and altered fat distribution.
100 mg
KLOW
Blend of GHK-Cu, BPC-157, TB-500 and KPV. Studies on the individual components do not evaluate the blend.